Latest Breaking News On - உச்சம் மருத்துவ ஆராய்ச்சி - Page 1 : vimarsana.com

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJacky vonderscherStephena harrisonKostenloser wertpapierhandelPietro scalfaroAnnie florence loyerPinnacle clinical researchFrench infectiology research centerAlcoholic steato hepatitisPrincipal investigatorMedical directorPinnacle clinicalChief executive officerNon alcoholic steato hepatitisBile acidFlorence loyer

Study Published in Nature Medicine Shows Investigational

Study Published in Nature Medicine Shows Investigational
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesStephen harrisonChristina tartagliaKitty yaleExchange commissionPinnacle clinical researchNature medicineSerious adverse eventsSouth sanPrivate securities litigation reform actAnnual reportஒன்றுபட்டது மாநிலங்களில்ஸ்டீபன் ஹாரிசன்கிறிஸ்டினா டார்டாக்லியாகிட்டி யேல்பரிமாற்றம் தரகு

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH) CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH. “NASH is the quintessential complex disease, involving the dysregulation of numerous biological pathways and impacting an enormous, heterogenous global population,” said Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visi

United statesUnited kingdomSan antonioAlison schecterStephena harrisonPinnacle clinical researchUniversity of oxfordDrug administrationGlobal liver instituteMedical directorBill hinshawChief executive officerNon alcoholic steatohepatitisEndogenous metabolic modulatorsPrivate securities litigation reform actAnnual report

ChronWell, Inc Adds Stephen Harrison, MD to Advisory Board

Share this article FORT LAUDERDALE, Fla., Feb. 17, 2021 /PRNewswire/ ChronWell, Inc., a digital health and technology-enabled remote care management company, today announced that Stephen Harrison, MD, FACP, FAASLD, has been added to the company s Board of Advisors. I am excited about the prospect of working with the ChronWell team to further it s important work in using data and digital tools to help patients and practices together achieve better outcomes, said Dr. Harrison. With ChronWell s deep experience in harnessing clinical data, and scientific approach, I m anticipating great strides in digital healthcare in a variety of specialties, beginning with gastroenterology and liver disease.

Joe rubinsztainKimberley sirkMatt schreiberStephen harrisonSaint louis universityChronwell incUniversity of oxfordUniversity of mississippi school medicineRadcliffe department of medicineBrooke army medical centerPinnacle clinical researchSummit clinical researchMississippi schoolSaint louisInternal medicineVisiting professor

Can-Fite Reports on Progress With Its Namodenoson NASH Program

Can-Fite Reports on Progress With Its Namodenoson NASH Program Can-Fite Reports on Progress With Its Namodenoson NASH Program Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis (NASH) treatment: The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders (KOLs) in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involved in the design of Namodenosons successfully completed Phase II study in NAFLD/NASH which

New yorkUnited statesFite biopharmaMotti farbsteinPnina fishmanStephena harrisonScott friedmanExchange commissionDivision of liver diseasesPinnacle clinical researchIcahn school of medicine at mount sinaiFite biopharma ltdDrug administrationCan fite biopharmaKey opinion leadersLiver diseases